Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07117760) titled 'Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer' on Aug. 5.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: First Affiliated Hospital of Fujian Medical University
Condition:
Prostate Cancer
Intervention:
Drug: 225Ac-LNC1011
Recruitment Status: Recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: April 22, 2025
Target Sample Size: 20
Countries of Recruitment:
China
To know more, visit https://clinicaltrials...